Clinical Trial

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn what happens to doravirine (DOR) and islatravir (ISL) in a healthy lactating female's body over time. Researchers want to learn if DOR and ISL are in breast milk.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-07-18; most recent amendment 2026-02-19.
Status change: Active, Not Recruiting → Completed 2026-02-19
Status change: Completed → Active, Not Recruiting 2026-01-21
Status change: Recruiting → Completed 2025-12-17
Status change: Not Yet Recruiting → Recruiting 2025-10-02
Trial Details
NCT Number NCT07086079
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 12 participants
Start Date 2025-09-26
Primary Completion 2025-12-08 (estimated)
Study Completion 2026-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-20